Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.
You may also be interested in...
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Before pivotal depression data in 2021 attempt to redeem zuranolone after a failed Phase III study, the company will report Phase II results for next-gen GABA modulator SAGE-324 in essential tremor.